Adjunktive Therapie der Sepsis

Literatur

• 1 Dellinger R P, Carlet J M, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall J C, Parker M M, Ramsay G, Zimmerman J L, Vincent J L, Levy M M. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.  Intensive Care Med. 2004;  30 536-555
• 2 Annane D, Sébille V, Charpentier C, Bollaert P E, Francois B, Korach J M, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaut P, Bellissant E. Effect of treatment with low doses of hydrocortisone on mortality in patients with septic shock.  JAMA. 2002;  288 862-871
• 3 Bernard G R, Vincent J-L, Laterre P F, LaRosa S P, Dhainaut J F, Lopez-Rodriguez A, Steingrub J S, Garber G E, Helterbrand J D, Ely E W, Fisher C J. The Recombinant Human Activated Protein C Worldwide Evaluationin Severe Sepsis (PROWESS) Study Group . Efficacy and safety of recombinant human activated protein C for severe sepsis.  New Engl J Med. 2001;  344 699-709
• 4 Ligtenberg J J, Zijstra J G. The relative adrenal insufficiency syndrome revisited: which patients will benefit from low-dose steroids?.  Curr Opin Crit Care. 2004;  10 456-460
• 5 Keh D, Boehnke T, Weber-Carstens S, Schulz C, Ahlers O, Bercker S, Volk H D, Doecke W D, Falke K J, Gerlach H. Immunologic and hemodynamic effects of „low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study.  Am J Respir Crit Care Med. 2003;  167 512-520